These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25959702)

  • 41. Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region.
    Irving WL; Rupp D; McClure CP; Than LM; Titman A; Ball JK; Steinmann E; Bartenschlager R; Pietschmann T; Brown RJ
    Antiviral Res; 2014 Oct; 110():52-9. PubMed ID: 25057759
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy.
    Cento V; Landonio S; De Luca F; Di Maio VC; Micheli V; Mirabelli C; Niero F; Magni C; Rizzardini G; Perno CF; Ceccherini-Silberstein F
    Antivir Ther; 2013; 18(4):645-8. PubMed ID: 23411358
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is hepatitis C virus NS3 protease quasispecies heterogeneity predictive of progression from cirrhosis to hepatocellular carcinoma?
    Vallet S; Gouriou S; Nkontchou G; Hotta H; Vilerio M; Legrand-Quillien MC; Beaugrand M; Trinchet JC; Nousbaum JB; Dény P; Gaudy C; Goudeau A; Picard B; Payan C
    J Viral Hepat; 2007 Feb; 14(2):96-106. PubMed ID: 17244249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
    Sheaffer AK; Lee MS; Hernandez D; Chaniewski S; Yu F; Falk P; Friborg J; Zhai G; McPhee F
    Antivir Ther; 2011; 16(5):705-18. PubMed ID: 21817192
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors.
    Cento V; Mirabelli C; Salpini R; Dimonte S; Artese A; Costa G; Mercurio F; Svicher V; Parrotta L; Bertoli A; Ciotti M; Di Paolo D; Sarrecchia C; Andreoni M; Alcaro S; Angelico M; Perno CF; Ceccherini-Silberstein F
    PLoS One; 2012; 7(7):e39652. PubMed ID: 22792183
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in São Paulo state.
    Moreira RC; de Torres Santos AP; Lisboa-Neto G; Mendes-Corrêa MCJ; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; de Castro VFD; Pinho JRR
    Arch Virol; 2018 Oct; 163(10):2757-2764. PubMed ID: 29961118
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C.
    López-Labrador FX; He XS; Berenguer M; Cheung RC; González-Candelas F; Wright TL; Greenberg HB
    J Med Virol; 2004 Apr; 72(4):575-85. PubMed ID: 14981760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors.
    Ferraro D; Urone N; Di Marco V; Craxì A
    Infect Genet Evol; 2014 Apr; 23():80-5. PubMed ID: 24508244
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256.
    Mo H; Hedskog C; Lawitz E; Brainard DM; Yang J; Delaney W; Worth A; Miller MD
    Antiviral Res; 2017 Apr; 140():151-157. PubMed ID: 28132867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
    Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
    Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genotypic analysis of HCV 1a by sequencing of the NS3 proteasic region in simeprevir therapy candidates.
    Liberti A; Raddi A; Cuomo N
    Infez Med; 2016 Dec; 24(4):272-277. PubMed ID: 28011961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy.
    Svarovskaia ES; Martin R; McHutchison JG; Miller MD; Mo H
    J Clin Microbiol; 2012 Oct; 50(10):3267-74. PubMed ID: 22837328
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NS3 Variability in Hepatitis C Virus Genotype 1A Isolates from Liver Tissue and Serum Samples of Treatment-Naïve Patients with Chronic Hepatitis C.
    D'Aliberti D; Cacciola I; Musolino C; Raffa G; Filomia R; Alibrandi A; Benfatto S; Beninati C; Saitta C; Giosa D; Romeo O; Raimondo G; Pollicino T
    Intervirology; 2018; 61(1):1-8. PubMed ID: 30021203
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.
    Serre SB; Jensen SB; Ghanem L; Humes DG; Ramirez S; Li YP; Krarup H; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3563-78. PubMed ID: 27021330
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
    Franco S; Clotet B; Martínez MA
    Virus Res; 2008 Feb; 131(2):260-70. PubMed ID: 18037183
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
    Susser S; Vermehren J; Forestier N; Welker MW; Grigorian N; Füller C; Perner D; Zeuzem S; Sarrazin C
    J Clin Virol; 2011 Dec; 52(4):321-7. PubMed ID: 21924672
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus.
    Holland-Staley CA; Kovari LC; Golenberg EM; Pobursky KJ; Mayers DL
    Arch Virol; 2002 Jul; 147(7):1385-406. PubMed ID: 12111414
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism.
    McCloskey RM; Liang RH; Joy JB; Krajden M; Montaner JS; Harrigan PR; Poon AF
    J Infect Dis; 2015 Apr; 211(8):1288-95. PubMed ID: 25389307
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatitis C virus of subtype 2l in Marseille, southeastern France.
    Aherfi S; Glazunova O; Borentain P; Botta-Fridlund D; Chiche L; Bregigeon S; Motte A; Tamalet C; Colson P
    Intervirology; 2015; 58(1):6-13. PubMed ID: 25592333
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.
    Guo Z; Black S; Hu Y; McMonagle P; Ingravallo P; Chase R; Curry S; Asante-Appiah E
    J Biol Chem; 2017 Apr; 292(15):6202-6212. PubMed ID: 28228479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.